A Robust IPO Market--even for Devices?
Anyone who stood in the packed room at this year's Chase Hambrecht & Quist meeting in San Francisco in early January for the presentation by e-commerce player Neoforma.com Inc. could hardly be surprised by the results of the company's IPO, which went out the week following, raising $91 million for the B2B supply chain manager. But as well as the Neoforma public offering did, it was, arguably, nothing compared to the IPO of Aspect Medical Systems Inc., a manufacturer of depth-of-anesthesia monitoring devices.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.